Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma

Tsung-I Hsu,Yi-Ping Chen,Rong-Lin Zhang,Zih-An Chen,Cheng-Hsun Wu,Wen-Chang Chang,Chung-Yuan Mou,Hardy Wai-Hong Chan,Si-Han Wu

DOI: https://doi.org/10.1021/acsami.4c04289

IF: 9.5

2024-04-18

ACS Applied Materials & Interfaces

Abstract:While temozolomide (TMZ) has been a cornerstone in the treatment of newly diagnosed glioblastoma (GBM), a significant challenge has been the emergence of resistance to TMZ, which compromises its clinical benefits. Additionally, the nonspecificity of TMZ can lead to detrimental side effects. Although TMZ is capable of penetrating the blood-brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. This study...

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to overcome the blood - brain - tumor barrier (BBTB) in order to improve the effectiveness of glioblastoma (GBM) treatment that is resistant to temozolomide (TMZ). Specifically, it is mentioned in the study that although TMZ plays a central role in the treatment of newly - diagnosed GBM, the emergence of its resistance severely limits the clinical efficacy. In addition, the non - specificity of TMZ may lead to side effects. Therefore, this study aims to develop a targeted therapy to bypass the resistance mechanism and reduce off - target effects.

To achieve this goal, the research team introduced a new nanocarrier system - polyethylene glycol - modified mesoporous silica nanoparticles (C8 - MSN) for the delivery of docetaxel (DTX). This new carrier system is designed to solve the above problems in the following ways:

1. **Improve the ability of drugs to penetrate the BBTB**: C8 - MSN is surface - modified and can effectively penetrate the BBTB, thereby delivering drugs to the tumor area.
2. **Enhance the biocompatibility and stability of drugs**: C8 - MSN exhibits good biocompatibility in vitro and has no hemolytic activity at the treatment concentration.
3. **Improve the drug - loading capacity and release efficiency of drugs**: C8 - MSN can efficiently load DTX and slowly release it in physiological solutions, maintaining the efficacy of the drugs.
4. **Reduce side effects**: Compared with free DTX, DTX@C8 - MSN significantly reduces side effects, prolongs the survival time of mice, and significantly reduces the tumor volume.

Through these methods, the research team hopes to provide an effective and targeted treatment strategy to overcome the limitations in the current treatment of TMZ - resistant GBM.